Randomized Phase III Study of mFOLFOX7 or CAPOX plus Bevacizumab versus 5-Fluorouracil/Leucovorin or Capecitabine plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer (JCOG1018, RESPECT)
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: A: Fluoropyrimidine (5-FU/LVor capecitabine) + bevacizumab B: Fluoropyrimidine (5-FU/LV or capecitabine) + oxaliplatin + bevacizumab Primary outcome(s): Progression-free survival Study Design: Parallel Randomized
创建时间：
2012-09-15
